DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV? - PowerPoint PPT Presentation

daa s in the treatment of hcv the beginning of the end or the end of the beginning for hcv n.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV? PowerPoint Presentation
Download Presentation
DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

play fullscreen
1 / 66
DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?
256 Views
Download Presentation
zagiri
Download Presentation

DAA ’ s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. DAA’s in the treatment of HCV: The Beginning of the end or the end of the beginning for HCV?

  2. HCV-Related Cirrhosis Is Projected to Peak Over the Next 10 Years

  3. Sustained Virologic Response Improves Overall Survival in Chronic HCV with Advanced Fibrosis

  4. DAAs as Components of New Treatment Paradigm for Hepatitis C

  5. Eric the Sailor

  6. The story continues

  7. Interferon has a Dual Mechanism of Action: Viral Inhibition and Immune Modulation

  8. The addition of RBV Significantly Accelerates Viral Decay

  9. Pharmacokinetics of Once Daily Compared with Twice Daily Regimen of Ribavirin

  10. Eric’s HCV Treatment course

  11. Definitions of Response

  12. DAAs - Key Characteristics

  13. Protease Inhibitor DAAs in Clinical Trials

  14. 5 Non Nucleoside Polymerase Inhibitors

  15. 4 Nucleoside Analogue Polymerase Inhibitors

  16. 4 NS5A Inhibitors

  17. 3 Other Classes

  18. Eric Update

  19. Eric comes ashore

  20. Rash Decisions

  21. Progress on study

  22. Eric Week 24 to 48 and 72

  23. Newly Approved HCV Agents: Telaprevir and Boceprevir

  24. Treatment Naïve HCV G1

  25. Sprint 2 Boceprevir Naïve

  26. Sprint 2 SVR and Relapse Rates

  27. SPRINT-2 and RESPOND-2: HCV G1 Subtype as a Predictor of SVR in Patients with Poor IFN Response (BOC Arms Combined)

  28. Patients With Poor Interferon Response and Fail Treatment Are More Likely to Have RAVs

  29. Changes in HCV RNA over Time During Previous Phase I Studies (101/103)

  30. C219: HCV RNA Values over Time (Week 8 Interim Analysis, TVR-exposed)

  31. MK 5172 Second Generation PI

  32. Advance: SVR and Relapse Rates

  33. Previously Treated Patients HCV G1

  34. Respond-2

  35. Respond-2

  36. REALIZE: Insulin resistance was not an independent determinant of SVR

  37. REALIZE: Impact of anemia/RBV dose reduction on SVR